10 February 2023 - director dealing
The AIM-listed world-leading liquid biopsy company has announced that CEO Andrew Newland and Finance Director Ian Griffiths have both acquired shares in the company. Andrew Newland purchased 125,000 shares in the company on 9 February at 28.75p each, whilst Ian Griffiths purchased 30,000 shares at 29.175p on the same date. The share price of the company stands at around the lowest level for ten years and it is worth pointing out that it reached a high of 155p last year. The strong rise in the share price at that . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
